An Open Label, Single Center, Randomized, Two-way Crossover Parallel Group, Trial to Assess the Mechanism of Action of a Bi-layer Swallowable Tablet (Immediate Release and Sustained Release) Containing Calcium Carbonate Antacid in an Overnight and Day Application as Compared With a Standard, Non-layered (Immediate Release) Calcium Carbonate Swallow Tablet in Fed Healthy Male Participants.

Researchers are looking for a better way to treat people who have heartburn, indigestion, and problems due to excessive stomach acid. These are common problems which can affect daily life and disturb sleep during the night-time. Heartburn is the burning sensation or pain in the chest which occurs when stomach acid rises up in the food pipe (esophagus).
Calcium carbonate tablets are used to treat heartburn, indigestion, and related digestive problems. Calcium carbonate works by neutralizing the excess acid in the stomach. The study treatment is a new bi-layer calcium carbonate tablet that has two layers. One layer quickly releases calcium carbonate aimed to provide quick relief (called immediate release) while the other layer releases calcium carbonate slowly to make the relief last longer (called sustained release).
In this study, bi-layer calcium carbonate tablets will be given to healthy men for the first time. This study will provide information on how the new bi-layer tablet works inside the body.
The main purpose of this study is to learn about how the new bi-layer calcium carbonate tablet changes the average acidity levels (measured using pH) compared to the standard calcium carbonate tablet during the night-time.
For this, researchers will measure the acidity levels in the upper part of the stomach at regular intervals during the night-time.
The participants will be randomly (by chance) assigned to one of two treatment groups:
Participants in the first group will take the treatments at night.
Participants in the second group will take the treatments during the day.
All participants in both groups will take 2 bi-layer tablets and 2 standard tablets after a meal with a gap of 6 to 8 days between treatments. However, in each group, half the participants will receive the bi-layer tablets first while the other half will receive the standard tablets first.
Each participant will be in the study for around 52 days with up to 4 visits to the study site. This includes:
1. visit about 28 days before the treatment starts during which the doctors will confirm that the participant can take part in the study
2. visits for treatment with a gap of 6-8 days between each treatment, and
1 visit 7 to 14 days after the treatment ends during which the doctors will monitor the participants' health.
During the study, the doctors and their study team will:
check participants' overall health by performing tests such as blood and urine tests, and check heart health using an electrocardiogram (ECG)
take images of the stomach at different times after taking the treatment
measure acidity level (pH) using a device called pH probe that is inserted into the upper part of the stomach
ask the participants questions about how easy it is to take the study treatment
ask the participants what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think it is related to the study treatment, or not.
As this study is conducted in healthy men who will not gain any benefit from this treatment, access to the study treatment after the study is not planned.

Start Date06 Mar 2024

Sponsor / Collaborator

Bayer AG

RBR-7hqhj3y / Not yet recruitingNot ApplicableIIT

Use of calcium carbonate supplementation to prevent Pre-eclampsia in pregnant women high risk: randomized clinical trial

Start Date10 Jan 2024

Sponsor / Collaborator-

NCT06042985 / Not yet recruitingPhase 4IIT

Comparison of the Absorption of Calcium Citrate and Calcium Carbonate in Patients With an RYGB, LSG, and OAGB A Double-blind, Randomized Cross-over Trial

The precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

Start Date01 Dec 2023

Sponsor / Collaborator-

100 Clinical Results associated with Calcium carbonate

100 Translational Medicine associated with Calcium carbonate

100 Patents (Medical) associated with Calcium carbonate

3,040

Literatures (Medical) associated with Calcium carbonate

01 Jan 2025·Biomaterials

Editorial Note: ‘The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis’ Biomaterials, 296 (2023), 122059

01 Jan 2025·Biomaterials

Local delivery of carboplatin-loaded hydrogel and calcium carbonate enables two-stage drug release for limited-dose radiation to eliminate mouse malignant glioma

Article

Author: Liang, Hsiang-Kuang Tony ; Wei, Ming-Feng ; Hsu, Cheng-Yi ; Chen, Liang-Hsin ; Lin, Jason ; Lin, Feng-Huei

Postoperative radiotherapy remains the gold standard for malignant glioma treatment. Clinical limitations, including tumor growth between surgery and radiotherapy and the emergence of radioresistance, reduce treatment effectiveness and result in local disease progression. This study aimed to develop a local drug delivery system to inhibit tumor growth before radiotherapy and enhance the subsequent anticancer effects of limited-dose radiotherapy. We developed a compound of carboplatin-loaded hydrogel (CPH) incorporated with carboplatin-loaded calcium carbonate (CPCC) to enable two-stage (peritumoral and intracellular) release of carboplatin to initially inhibit tumor growth and to synergize with limited-dose radiation (10 Gy in a single fraction) to eliminate malignant glioma (ALTS1C1 cells) in a C57BL/6 mouse subcutaneous tumor model. The doses of carboplatin in CPH and CPCC treatments were 150 μL (carboplatin concentration of 5 mg/mL) and 15 mg (carboplatin concentration of 4.1 μg/mg), respectively. Mice receiving the combination of CPH-CPCC treatment and limited-dose radiation exhibited significantly reduced tumor growth volume compared to those receiving double-dose radiation alone. Furthermore, combining CPH-CPCC treatment with limited-dose radiation resulted in significantly longer progression-free survival than combining CPH treatment with limited-dose radiation. Local CPH-CPCC delivery synergized effectively with limited-dose radiation to eliminate mouse glioma, offering a promising solution for overcoming clinical limitations.

01 Dec 2024·Rice

OsNAC103, a NAC Transcription Factor, Positively Regulates Leaf Senescence and Plant Architecture in Rice

Article

Author: Wang, XinYi ; Hu, Youchuan ; Song, Juan ; Sun, Lina ; Yang, Xiaoying ; Xu, Hanqin ; Ning, Xiaotong ; Zhang, Siju ; Luan, Weijiang ; Liang, Shanshan ; Yang, Qi ; Pang, Mengzhen ; Liu, Haiyan

AbstractLeaf senescence, the last stage of leaf development, is essential for crop yield by promoting nutrition relocation from senescence leaves to new leaves and seeds. NAC (NAM/ATAF1/ATAF2/CUC2) proteins, one of the plant-specific transcription factors, widely distribute in plants and play important roles in plant growth and development. Here, we identified a new NAC member OsNAC103 and found that it plays critical roles in leaf senescence and plant architecture in rice. OsNAC103 mRNA levels were dramatically induced by leaf senescence as well as different phytohormones such as ABA, MeJA and ACC and abiotic stresses including dark, drought and high salinity. OsNAC103 acts as a transcription factor with nuclear localization signals at the N terminal and a transcriptional activation signal at the C terminal. Overexpression of OsNAC103 promoted leaf senescence while osnac103 mutants delayed leaf senescence under natural condition and dark-induced condition, meanwhile, senescence-associated genes (SAGs) were up-regulated in OsNAC103 overexpression (OsNAC103-OE) lines, indicating that OsNAC103 positively regulates leaf senescence in rice. Moreover, OsNAC103-OE lines exhibited loose plant architecture with larger tiller angles while tiller angles of osnac103 mutants decreased during the vegetative and reproductive growth stages due to the response of shoot gravitropism, suggesting that OsNAC103 can regulate the plant architecture in rice. Taken together, our results reveal that OsNAC103 plays crucial roles in the regulation of leaf senescence and plant architecture in rice.

News (Medical) associated with Calcium carbonate

08 Aug 2024

·www.echemi.com

After 2023 Snub, Amneal Clinches Approval for Extended-Release Parkinson's Disease Med Crexont

After a major setback in 2023, Amax Pharmaceuticals finally ushered in a brilliant victory in the United States, its signature innovative delayed release Parkinson's disease treatment drug - Crexont, successfully obtained the authoritative approval of the United States Food and Drug Administration (FDA). This unique oral calcium carbonate/levodopa (CD/LD) extended-release formulation opens a new chapter in the treatment of patients with Parkinson's disease with its superior efficacy and convenience, not only significantly extending their "well" period, but also reducing the number of burdensome daily doses to three times, greatly improving patients' quality of life. The FDA accepted Crexont's application after a thorough review and analysis of the detailed Phase III clinical trial data submitted by Amax. In this critical clinical trial of RISE-PD, Crexont stood out for its exceptional performance, providing patients with an additional 30 precious minutes of "good" time per day compared to traditional ready-to-release CD/LD. In addition, its average daily frequency of taking only three times, compared with five times for traditional drugs, undoubtedly brings unprecedented convenience to patients. The successful approval of Crexont is undoubtedly a significant milestone in the treatment of Parkinson's disease. In the face of the large population of patients in the United States - about 1 million people with Parkinson's disease, and about 90,000 new cases each year, the introduction of Crexont has undoubtedly brought unprecedented hope for patients. The co-ceos of Amax Pharmaceuticals, Chirag Patel and Chintu Patel, could not contain their excitement, saying that it is their greatest honor to bring this epoch-making new treatment to Parkinson's disease patients in the United States. At the same time, the company is also confidently planning to bring this innovative treatment to the international market. However, behind the success is often accompanied by unremitting efforts and challenges. Amax had previously been rejected by the FDA because of insufficient safety data on Crexont. This setback did not break them, but inspired them to be more determined and more rigorous. Now, with the successful approval of Crexont, the drug is expected to generate annual sales of up to $300 million to $500 million, further solidifying its leading position in the treatment of Parkinson's disease. It's worth noting that Amax is not alone. Abbott and Newrod Pharmaceuticals, among others, have faced similar regulatory challenges on the road to developing new levodopa preparations. These experiences show that despite the difficulties ahead, pharmaceutical companies are still working hard to find better treatments for Parkinson's disease. Amax's success has undoubtedly set an example for the entire industry, and has brought more treatment options and light of hope to patients with Parkinson's disease.

Phase 3Drug ApprovalClinical Result

27 Nov 2023

·www.prnewswire.com

Amorphical brings Scientific Breakthrough - Treating and Curing Chronic Inflammatory and Oncological Diseases

NES-ZIONA, Israel, Nov. 27, 2023 /PRNewswire/ -- An exclusive initiative by the Israeli biotechnology company Amorphical brings a breakthrough approach to treating a variety of chronic inflammatory and oncological diseases. Scientific Development and Breakthrough Amorphical has developed a pioneering technology to produce amorphous nano-minerals. The unique structure of these amorphous nano-minerals enables the efficient and rapid absorption of essential minerals in the body. Amorphous nano-minerals also possess a unique ability to stimulate healing mechanisms within the target damaged tissues. Amorphous Calcium Carbonate – Amorphical's Revolutionary Leading Product Calcium is a vital mineral for various physiological activities: bone formation, nerve conductivity, muscle function, boosting the immune system, and many other activities. Carbonate is a crucial molecule for maintaining the body's pH balance by neutralizing excess acidity. Treating the Cause for Disease, Not Just the Symptom Modern lifestyle, characterized by stress, unbalanced diet, and an increase in life expectancy, results in a reduced production of bicarbonate, essential for the proper function of the body. Consequently, the elevated tissue acidity impairs the ability to regulate inflammatory processes, ultimately leading to the development of chronic inflammatory as well as oncological diseases. Due to its unique structure and dissolving properties, unlike the crystalline mineral, the amorphous calcium carbonate can directly target inflamed or cancerous tissues. When amorphous carbonate calcium reaches the inflamed tissue, a neutralizing reaction occurs within the acidic environment. The resulting neutral environment does not support the inflammatory processes, leading to the desired healing. Neutralizing the acidic environment is also crucial in treating oncological diseases. Most oncological diseases are characterized by anaerobic respiration of cancer cells, creating an acidic environment within the tumor. This acidic environment supports the rapid division of cancer cells and the development of metastases, while preventing the immune system from attacking and eliminating the cancer cells. Neutralizing the acidic environment in the cancerous tissue by amorphous calcium carbonate inhibits the enhanced metabolic activity of the cancer cells, required for their rapid division. In parallel to the reduction in cancer cell proliferation, the neutralization of the acidic environment within the tumor allows the immune cells to resume their activity, and attack and destroy the cancer cells. To date, this is the sole technology capable of treating and curing a wide range of oncological diseases by transforming the cancerous environment into a healthy environment. Comparison to Current Medications Current medications for chronic inflammatory diseases primarily aim to alleviate symptoms rather than target the disease accelerator, which is the acidic environment within the inflamed tissue. In contrast, amorphous calcium carbonate neutralizes the acidic environment specifically in the inflamed tissue, and thus enables the healing of the inflammation. Conditions Suitable for Treatment by Amorphous Calcium Carbonate The innovative treatment with amorphous calcium carbonate promotes prompt and effective recovery across a variety of diseases: 1. Crohn's Disease, Multiple Sclerosis, Osteoporosis, Arthritis, Pulmonary diseases, and other chronic inflammatory diseases. 2. A wide range of oncological diseases including breast, prostate, colon, liver cancers, and more. 3. The treatment has proven to be highly effective in managing COVID-19. 4. The treatment significantly slows down aging processes and substantially improves the quality of life. Selected Scientific Publications on the Medical Activity of Amorphical's Nano-Amorphous Calcium Carbonate: Lung Cancer: Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity. Cancers (Basel). 2023 Jul 26;15(15):3785 Treatment for COVID-19: Sublingual and Inhaled Amorphous Calcium Carbonate for Hospitalized Patients with SARS-CoV-2: A Phase 1/2 Clinical Study. J Clin Trials. 2023 Vol.13 Iss. 4 No: 1000551 Effect on Mouse Embryos: The effect of amorphous calcium carbonate as a culture media supplement on embryonic development of murine sibling embryos. J Assist Reprod Genet. 2023 Oct;40(10):2409-2418 Additional articles describing the treatment with Amorphical's amorphous nano-minerals are presented on the company's website. For more information, please contact: Noga Nadel Erental - [email protected] Logo -

08 Aug 2023

·www.biospace.com

Biosenta announces further advances in research and development of Tri-Filler™

TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation. Ongoing development of new methods of production of Tri-Filler™ by Dr. Maen Husein of the Department of Chemical Engineering at the University of Calgary and his team have reduced aggregation and resulted in the production of Tri-Filler™ particles being more uniform in shape and morphology. Additionally, using these new production methods, Tri-Filler™ can now be produced continuously at a higher rate than previously achieved. The University of Calgary team continues to investigate the mechanism of encapsulation of calcium hydroxide with calcium carbonate with a view to improving Tri-Filler’s performance in industrial applications and exploring Tri-Filler’s ability to serve as an effective carbon sink. Preliminary testing conducted by SGS Canada Inc. using accelerated aging, indicates that Tri-Filler™ may have a shelf life of up to 99 years. Dr. Mehdi Mohammadi Ashani, a Postdoctoral Fellow in Microbiology and Bioengineering at the University of Calgary, continues to study Tri-Filler™ on its own and in combination with other materials, to assess its efficacy against a diverse range of microorganisms, encompassing gram-positive and gram-negative bacteria including S.aureus, P.aeruginosa, and E.coli as well as fungi, including C.albecan and C.auris. Lab testing of Tri-Filler™ as an anti-microbial has shown very promising results. Preliminary testing points to the Tri-Filler™ being effective in inhibiting the growth of both gram-positive and gram-negative bacteria and fungi. Of note, the addition of Tri-Filler™ in paint has demonstrated the capability to eradicate a broad selection of bacteria and more than 95% of fungi within a brief 10-minute duration. This anti-microbial activity has been shown to be effective to combat Candida auris (C.auris) fungus. This specific fungus presents a substantial global health risk, given its alarming rate of spread, as identified by the Centers for Disease Control and Prevention (CDC). These preliminary results show a potential for Tri-Filler™ to target C.auris infections in hospital and clinic settings. Further investigation by the University of Calgary team, experimentation and refinement of the Tri-Filler™ particle continue. Tri-Filler™ has been produced and tested in laboratory quantities and settings only. Biosenta and the University of Calgary team are in the process of assembling a bench-scale unit capable of producing Tri-Filler™ in more significant amounts to be used for commercial testing and as a precursor to developing and scaling up to a commercial plant. Biosenta has identified a number of industry partners with whom Biosenta and the University of Calgary team are in various stages of talks for further research and commercialization. These partnerships will be the subject of future press releases if and as agreements with such industry partners are entered into. For certainty, while the Company has had initial conversations with potential partners, these conversations are preliminary, and the Company has not entered into any definitive agreements with any such partners. Biosenta Biosenta Inc., a ground-breaking pioneer in the field of antimicrobial solutions, is on a mission to revolutionize the material world. We develop cutting-edge chemical compounds designed to eliminate harmful microorganisms such as bacteria, fungi, and viruses for household and industrial uses, while ensuring safety for both humans and the environment. Our aim is to address the escalating global health crisis of Antimicrobial Resistance (AMR). Our ground-breaking approach has birthed two main offerings: true™ Disinfectant: Our pioneering, broad-spectrum, anti-microbial, dual-action disinfectant is recognized by Health Canada for use in the fight against COVID-19. We designed it to be tough on germs but gentle on humans, causing no irritation or harm. With its long-lasting disinfecting power, it effectively kills bacteria, germs, mold, mildew, and viruses. Our true™ technology leads the charge against the threat of superbug pathogens. Tri-Filler™: Biosenta's flagship product, Tri-Filler™, symbolizes our commitment to transforming the material world. The “Tri” in Tri-Filler™ represents three key characteristics: Antimicrobial Power: Tri-Filler™ delivers impressive antimicrobial protection, preventing the regrowth of bacteria, fungi, mold, and viruses. It provides a critical defence against the escalating Antimicrobial Resistance (AMR) global health crisis. Material Enhancement: Ingeniously engineered by encapsulating calcium hydroxide with calcium carbonate, Tri-Filler™ is a food-grade, bio-compatible solution. It not only imparts antimicrobial properties but also enhances the strength, fire retardancy, and performance of various materials including plastics, paints, coatings, textiles, drywall and concrete. It fortifies these materials against forces and stresses that could cause damage or failure. Our accelerated aging tests show that this solution can maintain efficacy for up to an impressive 99 years. Eco-Efficiency: Tri-Filler™ represents a significant stride towards a greener future. By incorporating CO2 in the encapsulation process, Tri-Filler™ aids in reducing CO2 emissions, helping businesses in achieving their sustainability goals. Proudly Canadian, Biosenta is at the forefront of reshaping the material world for the better, tackling significant global health and environment challenges. We are committed to making the world a safer and healthier place. Forward-Looking Information This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”), including forward-looking statements relating to: anticipated production rates and continuity of production for Tri-Filler™, potential for improving Tri-Filler’s performance in industrial applications, use of Tri-Filler™ as a carbon sink, the potential shelf life of Tri-Filler™, Tri-Filler™ being effective in inhibiting the growth of both gram-positive and gram-negative bacteria and fungi targeting C.auris infections in hospital and clinic settings, further investigation by the University of Calgary, future publication of results, assembling of a bench-scale unit capable of producing Tri-Filler™ in more significant amounts to be used for commercial testing and the potential to develop and scale up to a commercial plant, identification of industry partners and entering into agreements with these partners. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. In particular, the results expressed in this press release are based on preliminary testing only, are subject to confirmation in further testing, and have not been tested in real world application or otherwise outside of a laboratory setting. Such risks, uncertainties, assumptions and factors also include, but are not limited to: future testing may not yield results as promising as initial results, results of testing in a laboratory setting may not be applicable to real life settings, assumptions in respect of developing and scaling up to a commercial plant, the ability of Biosenta to fund continued research and development, the availability of industry partners and the ability to successfully negotiate agreements and consummate transactions with them and the ability to be able to further commercialize Tri-Filler™. If any such assumptions become incorrect, or such risks actually occur, they could materially adversely affect the path to continued commercialization of Tri-Filler™ and, by extension, the Company’s business, financial condition or results of operations. In that case, the trading price of the Company’s common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Disclaimer The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. For further information please contact: Am Gill, President and CEO Biosenta Inc. Phone: 416-410-2019

Microbial therapy

100 Deals associated with Calcium carbonate

External Link

KEGG	Wiki	ATC	Drug Bank
D00932	Calcium carbonate	A12AA04 A02AC01	DB06724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperphosphatemia	JP	Takeda Pharmaceutical Co., Ltd.	-
Osteoporosis	CN	Haleon (Suzhou) Pharmaceutical Co. Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoparathyroidism	Phase 2	-	-	-
Gastroesophageal Reflux	Phase 1	JP	Otsuka Pharmaceutical Co., Ltd.	31 Oct 2017
HIV Infections	Phase 1	-	ViiV Healthcare Ltd.	01 Dec 2012
Bone metastases	Preclinical	IL	Amorphical Ltd.	01 Jun 2022
Castration-Resistant Prostatic Cancer	Preclinical	IL	Amorphical Ltd.	01 Jun 2022
Neoplasms	Preclinical	IL	Amorphical Ltd.	18 Jul 2018
Adrenocortical Carcinoma	Preclinical	IL	Amorphical Ltd.	25 Jun 2017
Secondary malignant neoplasm of lung	Preclinical	IL	Amorphical Ltd.	25 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02186600 (HOPS, CTgov)	Phase 3	Osteoporosis	276	Calcium Carbonate+Vitamin D3 (Control)	tamzkjokrf(ijtxkeuiyw) = dtriganzph hkuddksaue (zjumottegw, pgumeacceb - jytoagpthw) View more	-	27 Jun 2023
				Risedronate+Calcium Carbonate+Vitamin D3 (Risedronate)	tamzkjokrf(ijtxkeuiyw) = ectunaqtpg hkuddksaue (zjumottegw, swskzrrkbw - jvbftqpcbf) View more
MO814 (ERA2022)	Not Applicable	Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	qosrisxywe(sgrsrqngmw) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment iogwydrgks (sepzgocobr )	-	03 May 2022
				Calcium carbonate
NCT01696279 (CTgov)	Phase 2	Hyperphosphatemia \| Chronic Kidney Diseases	63	lanthanum carbonate (Part 2 + Part 3: Lanthanum Carbonate)	qsgtwbhcgb(lcsujhydhk) = wlqzokhmzy fuynyffjsm (qvgxccsfad, itsnfqmoyh - gyovyaqzex) View more	-	02 Jan 2020
				calcium carbonate (Part 2: Calcium Carbonate)	vkbabsjkbc(hwsrmktkgy) = gvltiygppr qluvkonhus (opfkgapguc, vpiqkpldyh - ndpqqewneu) View more
ASN2019	Not Applicable	-	37	Calcium Carbonate	escpgvzwjr(zxixrbcpte) = xywfcywucg bihubqdbbn (zfvpohbagx, 7 - 14) View more	Negative	05 Nov 2019
				Sevelamer	escpgvzwjr(zxixrbcpte) = frohdqdkac bihubqdbbn (zfvpohbagx, 3 - 19) View more
ASN2019	Not Applicable	-	53	Denosumab 60mg s.c.	(jabpoxfdgn) = Hypocalcemia is frequent in HD patients after use of denosumab. Intravenous calcium replacement is needed in patients with severe hypocalcemia cbfgapmtdj (dinlgzblck ) View more	Positive	05 Nov 2019
				Dicamax(cholecalciferol 1000 IU and calcium carbonate 1250mg)
NCT03089216 (CTgov)	Phase 4	Dentin Sensitivity	108	Combined Bleaching(2x20) (Combined Bleaching(2x20))	ktvvvqtlzt(raolfujpdz) = eveviwgkwx xlvpsaqazi (rosbvvwwkv, pyemlmqdtz - szxukkatwb) View more	-	05 Aug 2019
				Combined Bleaching (1x20) (Combined Bleaching(1x20))	ktvvvqtlzt(raolfujpdz) = yjzytrczfg xlvpsaqazi (rosbvvwwkv, dkmincrieq - unwhgqczvk) View more
NCT00436475 (CaDDM, CTgov)	Phase 1/2	Diabetes Mellitus, Type 2 \| Metabolic Syndrome \| Glucose Intolerance	92	Vitamin D (Vitamin D-Calcium)	xcdjkfxefs(wrwzhplicu) = iuvewgeltc fdstkhxbhl (zglmbaxgyv, iqjgwgcsmo - ztqpbjcrpb) View more	-	30 Jul 2019
				Vitamin D (Vitamin D Only)	xcdjkfxefs(wrwzhplicu) = iiqddjonih fdstkhxbhl (zglmbaxgyv, ddkfmsgjtr - cvybsigcpf) View more
ISN WCN2019	Not Applicable	-	-	Calcium Carbonate	rmfinljrrr(ukpeqqnmta) = vzhvjskyeu dylkdceotv (gkrpvwrpak )	-	01 Jul 2019
				Sevelamer Hydrochloride	rmfinljrrr(ukpeqqnmta) = ysbbejumsc dylkdceotv (gkrpvwrpak )
ASN2018	Not Applicable	osteocalcin \| bone alkaline phosphatase \| tartrate-resistant acid phosphatase 5b ... View more	65	Lanthanum Carbonate	lehpafqgpi(cdsoccckux) = byfmgabquc ptjucuzuav (kbvmcpacvo, 18.9 - 53.2) View more	Positive	23 Oct 2018
				Calcium Carbonate	lehpafqgpi(cdsoccckux) = evkvygkenx ptjucuzuav (kbvmcpacvo, 15.3 - 28.3) View more
ASN2016	Not Applicable	Maintenance	98	Oral calcium carbonate	tykyiwqosk(uexfwxcnwo) = reqfrwezia yjboxeqywb (vmwhlairiw ) View more	Negative	15 Nov 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis